M‐CAM expression as marker of poor prognosis in epithelial ovarian cancer
暂无分享,去创建一个
M. Gariboldi | F. Demichelis | S. Canevari | D. Di Vizio | M. Barbareschi | C. Doglioni | E. Galligioni | D. Mezzanzanica | C. Griso | E. Balladore | C. Pegoraro | S. Brugnara | D. Aldovini | M. Zannoni | B. Zeni
[1] Mattia Barbareschi,et al. TMABoost: an integrated system for comprehensive management of tissue microarray data , 2006, IEEE Transactions on Information Technology in Biomedicine.
[2] D. Montell,et al. Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.
[3] Andrea Bolognesi,et al. Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody , 2005, Journal of Cell Science.
[4] D. Bell,et al. Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.
[5] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[6] R. Schneider,et al. Endothelin-1 upregulates MCAM in melanocytes. , 2004, The Journal of investigative dermatology.
[7] Luigi Marchionni,et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2 , 2004, Oncogene.
[8] S. Canevari,et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma , 2004, Clinical Cancer Research.
[9] M. Herlyn,et al. Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. , 2004, Experimental cell research.
[10] I. Shih,et al. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.
[11] Gerhard Christofori,et al. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.
[12] Trevor Hastie,et al. Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.
[13] A. Sboner,et al. [Tissue microarrays in oncology]. , 2003, Pathologica.
[14] P. Brunet,et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration , 2003, Thrombosis and Haemostasis.
[15] B. Becker,et al. Upregulation of MCAM in primary bronchial epithelial cells from patients with COPD , 2003, European Respiratory Journal.
[16] M. Barbareschi,et al. High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis , 2003, Cancer.
[17] Peiyu Li,et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. , 2003, Blood.
[18] M. Loda,et al. CDX-2 Homeobox Gene Expression Is a Reliable Marker of Colorectal Adenocarcinoma Metastases to the Lungs , 2003, The American journal of surgical pathology.
[19] I. Petersen,et al. Expression of the Cell Adhesion Molecule CD146/MCAM in Non-Small Cell Lung Cancer , 2003, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.
[20] Suyun Huang,et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. , 2002, Cancer research.
[21] A. Le Bivic,et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. , 2001, Blood.
[22] M. Amin,et al. Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. , 2001, Gene.
[23] M. Amin,et al. Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues , 2001, The Prostate.
[24] M. Herlyn,et al. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication , 2001, Oncogene.
[25] A. Lippold,et al. Prognostic immunohistochemical markers of primary human melanomas , 2001, The British journal of dermatology.
[26] G. Viale,et al. p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast , 2001, The American journal of surgical pathology.
[27] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[28] O. Vainio,et al. HEMCAM/CD146 downregulates cell surface expression of beta1 integrins. , 2001, Journal of cell science.
[29] D. Lockhart,et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] Y. Bignon,et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). , 2000, International journal of oncology.
[31] I. Shih. The role of CD146 (Mel‐CAM) in biology and pathology , 1999, The Journal of pathology.
[32] A. D. Dei Tos,et al. Cyclin D3 expression in normal, reactive and neoplastic tissues , 1998, The Journal of pathology.
[33] M. Bar‐eli,et al. Melanoma progression–associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand , 1997 .
[34] J. Palazzo,et al. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. , 1997, The American journal of pathology.
[35] J. Johnson,et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. , 1997, Cancer research.
[36] J. Johnson,et al. Melanoma progression-associated glycoprotein MUC18/MCAM mediates homotypic cell adhesion through interaction with a heterophilic ligand. , 1997, International journal of cancer.
[37] S. Fox,et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. , 1996, Human pathology.
[38] Ross Ihaka,et al. Gentleman R: R: A language for data analysis and graphics , 1996 .
[39] Lawrence A. Donehower,et al. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.
[40] P. Allavena,et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.
[41] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[42] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[43] T E Walsh,et al. Reporting results. , 1969, Archives of otolaryngology.
[44] A. Satterfield,et al. TREATMENT , 1924, California and western medicine.